Your browser doesn't support javascript.
loading
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
Meulendijks, Didier; Jacob, Wolfgang; Voest, Emile E; Mau-Sorensen, Morten; Martinez-Garcia, Maria; Taus, Alvaro; Fleitas, Tania; Cervantes, Andres; Lolkema, Martijn P; Langenberg, Marlies H G; De Jonge, Maja J; Sleijfer, Stefan; Han, Ji-Youn; Calles, Antonio; Felip, Enriqueta; Kim, Sang-We; Schellens, Jan H M; Wilson, Sabine; Thomas, Marlene; Ceppi, Maurizio; Meneses-Lorente, Georgina; James, Ian; Vega-Harring, Suzana; Dua, Rajiv; Nguyen, Maitram; Steiner, Lori; Adessi, Celine; Michielin, Francesca; Bossenmaier, Birgit; Weisser, Martin; Lassen, Ulrik N.
Afiliación
  • Meulendijks D; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Jacob W; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany. wolfgang.jacob@roche.com.
  • Voest EE; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Mau-Sorensen M; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
  • Martinez-Garcia M; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
  • Taus A; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
  • Fleitas T; Department of Medical Oncology, CIBERONC, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain.
  • Cervantes A; Department of Medical Oncology, CIBERONC, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain.
  • Lolkema MP; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Langenberg MHG; Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands.
  • De Jonge MJ; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Sleijfer S; Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands.
  • Han JY; Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands.
  • Calles A; Center for Lung Cancer, National Cancer Center, Goyang, South Korea.
  • Felip E; START-Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain.
  • Kim SW; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Schellens JHM; Department of Oncology, Asan Medical Center, Seoul, South Korea.
  • Wilson S; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Thomas M; Utrecht Institute for Pharmaceutical Sciences (UIPS), University Utrecht, Utrecht, the Netherlands.
  • Ceppi M; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Meneses-Lorente G; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • James I; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Vega-Harring S; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn, United Kingdom.
  • Dua R; A4P Consulting Ltd, Discovery Park, Sandwich, United Kingdom.
  • Nguyen M; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Steiner L; Roche Molecular Systems Inc., Pleasanton, California.
  • Adessi C; Roche Molecular Systems Inc., Pleasanton, California.
  • Michielin F; Roche Molecular Systems Inc., Pleasanton, California.
  • Bossenmaier B; Pharma Research and Early Development, Roche Innovation Center, Basel, Basel, Switzerland.
  • Weisser M; Pharma Research and Early Development, Roche Innovation Center, Basel, Basel, Switzerland.
  • Lassen UN; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Clin Cancer Res ; 23(18): 5406-5415, 2017 Sep 15.
Article en En | MEDLINE | ID: mdl-28600476
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Receptor ErbB-3 / Neurregulina-1 / Neoplasias Tipo de estudio: Clinical_trials Límite: Female / Humans / Male Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Receptor ErbB-3 / Neurregulina-1 / Neoplasias Tipo de estudio: Clinical_trials Límite: Female / Humans / Male Idioma: En Año: 2017 Tipo del documento: Article